DRUG · Mapped RxNorm record
deferasirox
Normalized identity: deferasirox View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
NCT01159067
Study summary
ClinicalTrials.govDeferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
Iron Overloadverified · MONDO: iron poisoning
de Novo Myelodysplastic Syndromesunresolved
Disseminated Neuroblastomaunresolved
Recurrent Adult Acute Myeloid Leukemiaunresolved
Recurrent Adult Burkitt Lymphomaunresolved
Recurrent Adult Hodgkin Lymphomaunresolved
Recurrent Adult Lymphoblastic Lymphomaunresolved
Recurrent Grade 1 Follicular Lymphomaunresolved
Recurrent Grade 2 Follicular Lymphomaunresolved
Recurrent Grade 3 Follicular Lymphomaunresolved
Recurrent Mantle Cell Lymphomaunresolved
Recurrent Marginal Zone Lymphomaunresolved
Recurrent Neuroblastomaunresolved
Recurrent Ovarian Epithelial Cancerunresolved
Recurrent Ovarian Germ Cell Tumorunresolved
Recurrent Small Lymphocytic Lymphomaunresolved
Refractory Chronic Lymphocytic Leukemiaunresolved
Relapsing Chronic Myelogenous Leukemiaunresolved
Secondary Myelodysplastic Syndromesunresolved
Stage I Multiple Myelomaunresolved
Stage II Multiple Myelomaunresolved
Stage II Ovarian Epithelial Cancerunresolved
Stage III Adult Burkitt Lymphomaunresolved
Stage III Adult Hodgkin Lymphomaunresolved
Stage III Adult Lymphoblastic Lymphomaunresolved
Stage III Chronic Lymphocytic Leukemiaunresolved
Stage III Grade 1 Follicular Lymphomaunresolved
Stage III Grade 2 Follicular Lymphomaunresolved
Stage III Grade 3 Follicular Lymphomaunresolved
Stage III Mantle Cell Lymphomaunresolved
Stage III Marginal Zone Lymphomaunresolved
Stage III Multiple Myelomaunresolved
Stage III Ovarian Epithelial Cancerunresolved
Stage III Small Lymphocytic Lymphomaunresolved
Stage IIIA Breast Cancerunresolved
Stage IIIB Breast Cancerunresolved
Stage IIIC Breast Cancerunresolved
Stage IV Adult Burkitt Lymphomaunresolved
Stage IV Adult Hodgkin Lymphomaunresolved
Stage IV Adult Lymphoblastic Lymphomaunresolved
Stage IV Breast Cancerunresolved
Stage IV Chronic Lymphocytic Leukemiaunresolved
Stage IV Grade 1 Follicular Lymphomaunresolved
Stage IV Grade 2 Follicular Lymphomaunresolved
Stage IV Grade 3 Follicular Lymphomaunresolved
Stage IV Mantle Cell Lymphomaunresolved
Stage IV Marginal Zone Lymphomaunresolved
Stage IV Ovarian Epithelial Cancerunresolved
Stage IV Small Lymphocytic Lymphomaunresolved
Interventions
deferasiroxDRUG · verified · RxNorm: deferasirox
Sponsors & collaborators
City of Hope Medical Centerlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01159067 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.